in interstitial fluid (ISF) that bathes insulin-sensitive cells (21) . Several studies in animals (1; 2; 7; 12; 14; 21-23) provided evidence demonstrating a close correlation between glucose uptake and the concentration of insulin in lymph fluid. Jansson et al. (10) argued that collection of lymph may not provide correct information of the interstitial insulin concentration in insulin-sensitive tissues and suggested that the insulin concentration should be measured directly in the ISF. This was facilitated in human studies by the use of largepored membranes in the microdialysis sampling technique (11) . Since then, insulin concentrations have been estimated with microdialysis in human subcutaneous ISF (10) and repeatedly in human skeletal muscle tissue (8; 9; 18-20) .
To our knowledge, however, comparative measurements of insulin in subcutaneous adipose and skeletal muscle tissue have not been performed to date. Thus, it is not known whether there are tissue-specific differences in the interstitial insulin levels. Therefore, to explore insulinemia and potential differences at the level of human insulin-sensitive tissues, the need for paired insulin measurements in human muscle and subcutaneous adipose ISF per se was identified.
Though measuring in ISF, microdialysis -similarly to the lymph approach -has been finding significantly lower interstitial insulin levels compared to plasma. The data suggest the existence of an endothelial barrier for insulin (2; 3; 13) in combination with tissue clearance which leads to lower ISF insulin levels in subcutaneous and muscle tissue. Lately, microdialysis was used for ISF insulin estimations at physiological plasma insulin concentrations (9) . The insulin fraction in healthy subjects' skeletal muscle was found to be very low compared to the plasma concentration during an euglycemic insulin clamp. Low insulin fractions under such moderate hyperinsulinemic conditions had already been reported in 1994 by Castillo et al. (3) from the only known study of peripheral lymph insulin in humans. We argued whether these findings of low insulin fractions in ISF/lymph for moderate hyperinsulinemia could be verified using the beneficial features of a direct interstitial access by open-flow microperfusion together with that of the well-known 'No Net Flux' approach.
Therefore, the aim of this study was 1) to investigate ISF insulin levels simultaneously in skeletal muscle and subcutaneous adipose tissue in healthy subjects, and 2) to verify and quantify low peripheral ISF insulin fractions in healthy subjects during moderate hyperinsulinemia.
METHODS

Subjects
Nine healthy volunteers (age 27.2 ± 0.8 years, BMI 24.6 ± 0.92 kg/m 2 ; mean ± SE) participated in this study. Their mean fasting plasma glucose concentration was 5.2 ± 0.13 mM and their fasting plasma insulin averaged 55 ± 15 pM. None was taking any regular medication. Written informed consent was obtained after the purpose, nature, and potential risks of the study were explained to the subjects. The experimental protocol was approved by the local ethical committee.
Open-flow microperfusion
The principle of interstitial fluid sampling by open-flow microperfusion has been described in detail previously (6; 15; 17) . Briefly, a perforated (100 holes a 0. The ability of OFM catheters to recover large molecules at reasonable rates of relative recovery was demonstrated in a study of albumin (mol.wt. 68kDa) in muscle and s.c. adipose tissue (5), suggesting that the catheters also recover the smaller insulin molecule (5.9kDa)
effectively. Prior to this study, the sampling system was characterized in vitro regarding potential effects of unspecific binding of insulin as reported from microdialysis (10; 16; 19) .
The tests revealed an unchanged passage of insulin concentrations, i.e. no significant insulin binding to OFM material in the presence of 1% albumin in the perfusate.
No Net Flux calibration protocol
The 'No Net Flux' calibration protocol (NNF) or 'equilibrium method' was established in microdialysis by Lönnroth et al. (11) . It has been used either for direct quantification of ISF concentrations or for estimations of the relative 'recovery' of substances, including that for insulin. In OFM the protocol has so far been used for direct quantification of small molecules (e.g. glucose) and for human albumin (5) . In brief, known concentrations of the substance to be quantified in the interstitial space are added to the perfusate, in concentrations higher and 
Study Protocol
After fasting overnight, subjects arrived at 0700 a.m. and were investigated in a supine
position. An intravenous cannula was placed in a dorsal hand vein and the forearm kept in a 
Analytical methods
Plasma glucose levels were monitored using a glucose oxidase method (Beckman Glucose Analyzer II; Beckman Instruments, Fullerton, CA) with a coefficient of variation of 2%.
Serum samples (á 1ml), samples of the insulin perfusates (á 0.5ml) and the OFM effluents (á 15 µl) were immediately frozen at -80°C. Insulin was measured using a solid-phase twosite enzyme-linked immunosorbent assay (Mercodia Ultrasensitive Insulin ELISA, Mercodia-AB, Uppsala, Sweden). The assay was validated in-house for 10µl of ISF matrix revealing an actual detection limit of 2.52 pM, a lower and an upper limit of quantification (LLoQ and ULoQ) of 9 and 120pM and an inter-run/assay precision between 2.7% (ULoQ) and 10%
(LLoQ), respectively.
Calculations and statistics
After insulin analysis, any insulin concentration in perfusate (C in ) and effluent (C out ) was expressed as percentage of the corresponding serum insulin concentration. This was done to account for 1) intra-subject fluctuations of serum insulin and 2) individually different serum insulin levels. For each of the five insulin concentrations in perfusate (C in ) the net change of insulin during catheter passage (C out -C in ) was determined from the three corresponding effluent samples. The mean net change was calculated for each of the five triplicates, and finally the point of no net change (or 'No Net Flux') assessed from the five means by first order least mean square linear regression analysis.
The analysis of the data was performed with two different approaches: In the first approach analysis was done for each catheter separately (Table 1 ) (Analysis I). Separate analyses accounted for catheter-individual recoveries (slopes) of geometrically identical catheters.
Catheter-by-catheter analyses also allowed to compare the results between adjacent catheters.
The arithmetic mean of the adjacent catheters in one tissue bed was considered the subject's specific tissue result. The mean of the nine individual results was taken as the overall result.
Significance of differences between both tissue regions and between tissue and serum levels was tested at the P < 0.05 level using the non parametric Wilcoxon's signed-rank test.
In the second approach, the overall ISF insulin fraction and recovery for a tissue bed was assessed from a single regression analysis on the condensed data from all 9 subjects (Fig. 4) (Analysis II). This approach was known to ignore the catheter-and subject-individual recoveries (i.e. slopes of regression lines) entirely. However, the joint analysis allowed to depict all the data in a single graph with an average single regression line and the result obtained is supposed to be less vulnerable for outlying data. The variance of the linear regression and thus of the x-intercept was described by the borders of the 95% confidence interval.
RESULTS
Primed-constant intravenous infusion of insulin resulted in serum levels of 379.5 ± 18.8 pM (mean ± SEM; range 316.6 -517.6) within the predefined steady-state (SS) measurement period (0-570min). Intra-subject variability of serum insulin was described by an average coefficient of variation of 8.3 ± 1.0 % ( range 3.7 -12.2). Table 1 Using the non-individual data analysis (Fig. 4) compared to plasma. These ISF data suggested, that an endothelial barrier for insulin in combination with tissue clearance leads to lower insulin levels and altered kinetics in ISF compared to plasma. Subsequent microdialysis studies measured ISF insulin in skeletal muscle of healthy, obese and diabetic subjects (8; 18-20) in order to explore aspects of the delivery of insulin to ISF over the capillary wall. Also in those studies, high plasma insulin levels between ~900pM and ~4000pM were induced to achieve measurable insulin concentrations in microdialysis effluents. Thus, muscle insulin fractions between ~38% and ~54% of plasma in healthy subjects were found. Lately, microdialysis based estimations of ISF insulin were done at physiological plasma insulin concentrations (9) . Plasma insulin levels of approx. 500pM were induced in healthy subjects by means of an euglycemic, hyperinsulinemic clamp. Starting from a baseline muscle insulin fraction of 48% (of plasma)
that fraction was significantly reduced during the moderate hyperinsulinemic clamp to 12% at steady-state, whereas during an oral glucose tolerance test and similar plasma insulin levels the interstitial fraction remained fairly unchanged (43% of plasma). OFM catheters had once been used for insulin sampling from human muscle (3). However, the effluent insulin concentrations were not calibrated, and thus no insulin concentrations in ISF per se obtained.
In short, all previous studies with estimations of insulin in ISF per se were based on microdialysis effluents, and estimations were done in subcutaneous adipose tissue as well as in skeletal muscle, but never simultaneously in a study. As sampling membranes, calibration procedures, glycemia and insulinemia were different between the studies, comparison between the tissues' ISF insulin levels are not possible. Furthermore, quantification in the microdialysis studies was based on small effluent concentrations due to the membranes' low (3% -11%) insulin recovery which may add a significant error. These facts may explain some of the variation in the results for the ISF insulin fractions in microdialysis studies ( range 12% -54% in muscle tissue of healthy subjects). It may also be hypothesized, that some of the variation is due to a potential dependency of the resulting tissue fractions on the underlying vascular insulin levels. The relative low tissue fractions found at lower hyperinsulinemic levels provide an indication. We investigated the insulin concentrations in s.c. adipose and skeletal muscle ISF per se and performed paired measurements to allow for a comparison. Differences may arise from inherent methodological uncertainties and biological variability.
In our study the impact of uncertainties in the intercept assessment by regression was low due to the high insulin recoveries Due to the use of OFM the identification of contaminated ISF samples (reddish color, mostly from muscle) was possible, and by their exclusion unperceived adulteration of ISF results by plasma concentrations was prevented. We do not know whether morphological inhomogeneities within tissues or random positions of inserted catheters to e.g.
larger blood vessels could have contributed to variation. Finally, the means calculated from the individual catheters in both tissue beds (Table 1 ) match those from the less outliersensitive overall regression analysis (Fig. 5) .
In summary, our data suggest that the concentrations of insulin arising in healthy subjects Table 1 ). The dashed lines show the borders of the 95% confidence interval (95% CI) for the regression. Data are means ± SE; n=9. 
